All News
FDA Safety Warning: Avacopan and Serious Liver Injury
Yesterday the FDA issued a Drug Safety Communication alerting patients and health care professionals about postmarketing identification of serious (drug induced) liver injury, including fatal cases, associated with the use of avacopan (Tavneos) in patients with ANCA- associated vasculitis.
Read Article
Review: Rheumatoid Arthritis–Associated Interstitial Lung Disease
RA-ILD represents the most severe extra-articular manifestation of rheumatoid arthritis, affecting an estimated 1% of the adult population in the US and Northern Europe.
Read Article
Ixekizumab With Tirzepatide Efficacy in Obese Psoriatic Arthritis
The TOGETHER-PsA trial has demonstrated the efficacy and safety of ixekizumab (IXE) administered with tirzepatide (TZP) in adult active psoriatic arthritis (PsA) patients who were overweight or obese.
TENS Efficacy in Fibromyalgia
A randomized clinical trial of transcutaneous electrical nerve stimulation (TENS) in fibromyalgia showed meaningful improvement in pain for 6 months when combined with physical therapy (PT).
Read Article
What's it like to have #RA? PATTY "To find patients or doctors who can talk intelligently about RA is a welcomed relief. However, I prefer that those around me not know about me and my RA. I hope they don’t notice the changes in my hands or shoes or that I cannot wear my usual https://t.co/OQbXJrcyPp
Dr. John Cush RheumNow ( View Tweet)
After hours EHR catchup has been coined "Pajama time" by residents & physicians & contributes to burnout. Survey 9,731 YR 2 Family Med residents- spend 3+ hrs/d after wk on ambulatory EHRs. Pajama time assoc w/ less knowledge, professional satisfaction, more burnout. https://t.co/QSR7VM2T7u
Dr. John Cush RheumNow ( View Tweet)
Brepocitinib in Dermatomyositis
The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose.
https://t.co/YNxrVTIubb https://t.co/uFY3kMOvui
Dr. John Cush RheumNow ( View Tweet)
AFFINITY Study - Combination Biologic Therapy in PsA
A pilot trial assessed the efficacy and safety of the guselkumab+golimumab (COMBO) combination versus GUS monotherapy in active PsA (failing a prior tumor necrosis factor inhibitor (TNFi-IR) and showed superiority in ACR 50 https://t.co/f2CB8FnZMB
Dr. John Cush RheumNow ( View Tweet)
FDA has issued a drug safety warning for avacopan (Tavneos), dentifying 76 cases of drug-induced liver injury, including 7 cases of rare vanishing bile duct syndrome (VBDS). There were 8 deaths https://t.co/WkBhs1rNpf https://t.co/ZXdHsAJUOQ
Dr. John Cush RheumNow ( View Tweet)
The Mucosal Hypothesis of Rheumatoid Arthritis. Dr. Kristin Demoruelle
In this https://t.co/4UQlqwujiR 2026 podcast, Dr. Kristin Demoruelle explores the mucosal origins of RA and its implications.
🎧 Listen here: https://t.co/QxldIpYQC8
#Rheumatology #Autoimmunity #RNL2026 https://t.co/nz2dbwll14
Dr. John Cush RheumNow ( View Tweet)
DERM on RheumNow PODCAST (March 2026)
https://t.co/OGl34cH6z5 https://t.co/l7v1Xktl8r
Dr. John Cush RheumNow ( View Tweet)
Moral Distress (3.27.2026)
Dr. Jack Cush reviews the journal reports and news from RheumNow. This week we discuss moral distress, FM in PsA, Lyme Vax is back & hidden but tangible benefits of the MDHAQ.
https://t.co/LdNcsUcHc2 https://t.co/tRYeDhQ3hC
Dr. John Cush RheumNow ( View Tweet)
AXIS is an Intl prospective study of 409 psoriatic arthritis pts - found Axial involvement in 27.4% of pts. Axial PsA signif younger (45 vs 47.6 yrs) , male (56% vs 51.5%), more B27 positivity (22% vs 11%), inflammatory back pain (75% vs 43%), & ^CRP (53% vs 37%) https://t.co/XY5pf4BNNm
Dr. John Cush RheumNow ( View Tweet)
19 yr old male is Dx w/ Stills Dz (Fever 104F, pleuritis, organomegaly, WBC 24k, ESR 98, CRP 11 mg/L) - what drug do you prescribe first?
Dr. John Cush RheumNow ( View Tweet)
Portugese multicentre retrospective of 748 adults with JIA (age 28 yrs; Dz duration 21 yrs). Oligoarticular JIA was the most common subtype (29.9%). HTN (9%), psychiatric dz (8%), & osteoporosis (5%) were most prevalent comorbidities. bDMARD use reduced risk of psych Dz https://t.co/xCrTDxirlj
Dr. John Cush RheumNow ( View Tweet)
Psychiatrists have the highest Medicare opt-out rate (8% vs 1.2% MDs vs <3% Rheum), leading to a critical shortage of psychiatrists and more antipsychotic management to APRNs and PAs over the last decade. APPs Handle 40% of Antipsychotic Scripts https://t.co/wWnFcnXpRa https://t.co/WSQBEzvxgK
Dr. John Cush RheumNow ( View Tweet)
Myocarditis causes 17,000 deaths/Yr worldwide. Causes include A) iatrogenic/autoimmune: checkpoint inhibitors & gene therapy; B) High income countries: parvo B19, herpesvirus 6; C) low income: dengue, HIV, malaria and Trypanosoma cruzi (Chagas disease) https://t.co/en4OnhWPda https://t.co/urwkjlVeg6
Dr. John Cush RheumNow ( View Tweet)
19 yr old male is Dx w/ Stills Dz (Fever 104F, pleuritis, organomegaly, WBC 24k, ESR 98, CRP 11 mg/L) - what drug do you prescribe first?
Dr. John Cush RheumNow ( View Tweet)
Italian population study of 37996 RA (prevalence 0.54%) pts w/ and 12875 incident cases (incid rate 33.1/100K), there were 1288 deaths/8yrs (MR 21.3/1K), median age=83; SMR 1.28 (1.21 to 1.35), higher <45 yrs (2.15). Leading causes CV (37%), cancer (21%) & infxn (11%) https://t.co/wPx5iqW7Nl
Dr. John Cush RheumNow ( View Tweet)
Time to pregnancy (TTP) in 2 RA cohorts: PARA (n 245, 2002-10) vs PreCARA (n 215, 2011-23), latter Rx by T2T. Median TTP was 251d vs 91d (p<0·0001). Preg w/in 1 yrs was 42% v 77%. 61% PreCARA in remission https://t.co/qIHwXvfzMy https://t.co/1huBKiarhH
Dr. John Cush RheumNow ( View Tweet)
